Mona HEXAL

Quick links to important sections

Mona HEXAL

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mona HEXAL

The medicine Mona HEXAL is a combined hormonal contraceptive defined by its unique pairing of two synthetic steroid hormones, Chlormadinone Acetate and Ethinyl Estradiol. The product is manufactured by Hexal AG and is a prescription-only medicine (Rx).

Property Description
Active Ingredients Chlormadinone Acetate, Ethinyl Estradiol
Form Film-coated tablet (for oral use)
Pharmacological Class Hormonal Contraceptive (Systemic), Combined Estrogen/Progestin
Common Use Contraception (Pregnancy Prevention)
Origin Synthetic (steroid hormone derivatives)

What Type of Medicine is Mona HEXAL?

Mona HEXAL is a synthetic, combined oral contraceptive (COC) prescribed for systemic use, presented as a film-coated tablet for oral administration. The medicine belongs to the pharmacological class of Estrogens and Progestins and is specifically formulated as a monophasic pill with a consistent hormonal profile. This classification means every active tablet contains the same fixed amounts of both hormonal components throughout the active dosing cycle.

Composition: Chlormadinone Acetate and Ethinyl Estradiol

The core composition consists of the progestin Chlormadinone Acetate (CMA) and the estrogen Ethinyl Estradiol (EE). The inclusion of Chlormadinone Acetate is a distinguishing characteristic, as this progestin possesses antiandrogenic properties. Clinically, this means the compound actively works to counteract the biological effects of male-type hormones (androgens) in the body.

Primary Purpose and General Therapeutic Role

The primary purpose of Mona HEXAL is to provide reliable contraception, effectively preventing pregnancy by suppressing ovulation and altering the cervical environment. Beyond this function, the antiandrogenic properties are leveraged when patients require both contraception and hormonal support for certain androgen-related symptoms. This combination leads to a favorable outcome in managing various androgen-related manifestations.

Regulatory References

  1. NIH: PMC7382656

What side effects are possible with Mona HEXAL?

Possible Side Effects and Safety Information

The official safety profile for Mona HEXAL, a combination hormonal contraceptive, outlines adverse reactions categorized by their frequency and the body system affected. Safety information strictly derived from regulatory documents highlights both common expected reactions and serious, potentially life-threatening risks.

Frequency Category Common Examples by System Organ Class (SOC)
Very Common (Affects ge 1 in 10 users) Headache; gastrointestinal disorders (e.g., nausea)
Common (Affects ge 1 in 100 to < 1 in 10 users) Depressed mood, mood changes, nervousness; migraine; breast pain or tenderness; abdominal pain; weight gain; irregular bleeding

Serious Adverse Reactions and Safety Restrictions

Official regulatory sources identify the following serious adverse reactions:

  • Arterial and Venous Thromboembolic Events (VTE/ATE): This is a primary safety concern and includes deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (heart attack), and stroke. The risk is elevated, particularly during the first year of use.
  • Neoplasms: The product information documents an elevated risk of certain cancers, including breast cancer and benign or malignant liver tumours.

Use is contraindicated (absolutely restricted) for specific pre-existing conditions and circumstances. These include a history of or current thromboembolic disorders, severe or uncontrolled high blood pressure, certain heart diseases, known or suspected estrogen-dependent malignant tumours, and severe liver disease. Mona HEXAL is also contraindicated during pregnancy due to the potential risk of harm to the fetus.

Overdose and Emergency Response

The official regulatory profile for an overdose of this combined hormonal contraceptive (Mona HEXAL) is structured around the transient and non-life-threatening nature of acute excess steroid hormone ingestion.

Documented Overdose Manifestations

Feature Official Regulatory Statement
Severity Classification The overdose is generally not likely to be life-threatening or cause serious disability.
Expected Symptoms Documented manifestations include nausea, vomiting, headache, breast tenderness, and drowsiness.
Specific Delayed Sign A key physiological sign is heavy vaginal bleeding (withdrawal bleeding), typically commencing 2 to 7 days after the overdose.
Antidote Information No specific antidote is known; treatment is defined as symptomatic and supportive.

Immediate Actions and Emergency Response

In the event of a suspected overdose (taking more than the recommended amount), individuals are officially mandated to seek medical help right away and contact a poison control center for professional instruction. Management is limited to symptomatic and supportive treatment, with measures such as activated charcoal being considered in extreme cases. No reports of severe effects are apparent, including in cases of ingestion by children. Immediate emergency services must be called if the affected person collapses, has a seizure, or has trouble breathing.

Regulatory Summary

The regulatory framework classifies the acute risk as primarily non-severe, establishing that management focuses on professional observation and supportive care for the expected transient symptoms, while prescribing clear conditions that necessitate immediate, urgent medical intervention.

Therapeutic Uses of Mona HEXAL

What Mona HEXAL Treats: Main Uses and Benefits

The primary purpose of this medication is to provide effective, long-term contraception for women of reproductive age. In addition to this essential function, the utility is considered relevant across domains where additional symptomatic support is needed, such as in the management of mild to moderate acne vulgaris, symptoms of excessive sebum production, and conditions presenting with discomfort like heavy menstrual bleeding (menorrhagia) or menstrual pain (dysmenorrhea). The medication assists with maintaining functional stability when symptoms interfere with routine activities.

This medication is commonly used in scenarios where support for androgen-related manifestations is needed in addition to pregnancy prevention.

“This formulation is relevant in situations where patients experience androgen-related manifestations that interfere with daily functioning.”

The use of this medication generally contributes to cycle predictability and may help improve day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Androgen-Related Symptoms

The antiandrogenic properties are applied to ease the symptom burden in conditions such as acne and excessive oiliness, and may contribute to improved comfort during periods of heightened symptoms associated with acne and oiliness.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Mona HEXAL

Official regulatory information defines the population eligible to use this combined hormonal contraceptive (Chlormadinone Acetate/Ethinyl Estradiol) based on specific exclusion criteria, primarily revolving around thromboembolic risk and hormone-sensitive conditions.


Eligibility Scope

Classification Population Status as Defined by Regulatory Documents
Populations Allowed Women of reproductive age who require hormonal contraception and are free from all labeled contraindications.
Not Recommended Patients who are breastfeeding [WHO/CDC guidance] and those who are in the immediate postpartum period or immobilized following major surgery [SmPC guidance].

Absolute Contraindications

The medicine is strictly contraindicated and must not be used by patients who have a current or history of venous or arterial thromboembolic disorders (e.g., deep vein thrombosis, stroke) or a known hereditary predisposition for such events. Use is also prohibited for patients with current or history of Meningioma (due to the Chlormadinone component), severe hepatic disease or liver tumours, current or history of breast cancer, and known or suspected pregnancy. The medicine is also contraindicated if the patient has severe or multiple risk factors for thrombosis, such as severe uncontrolled hypertension or diabetes with vascular complications.

What should I know about interactions with other medicines?

The official regulatory profile for combined hormonal contraceptives containing Chlormadinone Acetate and Ethinyl Estradiol documents several categories of interaction patterns.

Metabolic Interactions and Reduced Effectiveness

Co-administration with enzyme-inducing medicinal products is documented to reduce the plasma concentration of the contraceptive hormones. This pharmacokinetic interaction is primarily due to the induction of hepatic enzymes, notably CYP3A4, which diminishes the product's effectiveness. Specific interacting substances include certain anticonvulsants (e.g., phenytoin, carbamazepine), the antibiotic rifampicin, and the herbal product St. John's Wort (Hypericum perforatum).

When taking these enzyme inducers, regulatory guidance mandates the use of an additional non-hormonal barrier method during co-administration and for a period of 28 days after stopping the interacting medicine.

Contraindicated Combinations

The combined hormonal contraceptive is strictly contraindicated for co-administration with specific Hepatitis C antiviral regimens, including combinations containing ombitasvir/paritaprevir/ritonavir pm dasabuvir or glecaprevir/pibrentasvir. This restriction is documented due to the risk of severe elevation of the liver enzyme Alanine Aminotransferase (ALT).

Effect on Co-administered Medicines

Furthermore, the contraceptive hormones may alter the clearance of other medicines. The ethinyl estradiol component is documented to reduce the plasma concentration of Lamotrigine by inducing its glucuronidation, an effect confirmed in regulatory labeling.

Mechanism of Action

Central Regulation of Hormone Signals

The medication acts as an agonist on hormone receptors to initiate a negative feedback loop that targets the Hypothalamic-Pituitary-Ovarian (HPO) axis in the brain. This action suppresses the release of key signaling hormones, Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), that would normally stimulate the ovary. This specific modulation of the central regulatory system contributes to the inhibition of ovum release.


Physical Barriers and Uterine Lining Modulation

The progestin component also exerts peripheral actions on reproductive tissues. It specifically alters the properties of the cervical fluid, making the mucus thicker and thereby restricting sperm mobility and passage. Concurrently, it modifies the structure of the uterine lining (endometrium), inducing changes in the endometrial structure. These peripheral mechanism domains create secondary physiological limitations that contribute to the overall physiological effects.

Dosage and Administration Information

Instruction Map: How to use Mona HEXAL — Administration Guidelines

Mona HEXAL is administered via the oral route as a film-coated tablet, following a highly structured, continuous regimen. The dosing schedule for this combined hormonal contraceptive is based on a 28-day cycle, which is repeated without interruption for long-term use.


Administration Scope

Key Feature Instruction
Route of administration: Oral administration.
Dosing schedule: One active tablet is taken daily for 21 consecutive days, followed by a 7-day hormone-free interval.
Timing in relation to meals (if applicable): Administration is independent of mealtimes (may be taken with or without food).
Preparation requirements (if applicable): Tablets are swallowed whole and must be taken in the order directed on the blister pack.
Age-group administration rules: Initiation of the regimen is generally avoided before 21 days postpartum.
Missed-dose rules: Specific, detailed protocols govern the required management steps and use of supplementary contraceptive methods following a missed active tablet.
Special procedural conditions: Tablets must be taken at the same approximate time each day to maintain a consistent dosing interval.

Instruction Classifications (High-Level)

Classification Description
Administration method type: Oral.
Frequency pattern: Daily, continuous cyclic pattern (21 days active / 7 days hormone-free).
Basis: Standardized protocols for combined hormonal contraceptives.
Use-context constraints: Intended for long-term, continuous, cyclic use.

Resulting Procedural Structure

Step sequence:

  • Administer one tablet orally and swallow it whole, adhering strictly to the order printed on the blister pack.
  • Maintain the same administration time daily throughout the 21-day active period.
  • Observe the 7-day hormone-free interval.

Connection to the Overall Use Protocol

This instruction map establishes a precise daily, cyclic rhythm for administering the medicine, defining the continuous schedule that must be perpetually repeated. This structure mandates adherence to a fixed administration time and strict sequence to maintain the intended use protocol.

Recent Clinical Evidence

Research evidence / Overview of studies for Mona HEXAL

Evidence for Use in Contraception (Pregnancy Prevention)

The research into the medication's primary function was studied for in large, non-randomized observational studies and controlled clinical trials. These studies were conducted to examine the outcome of pregnancy prevention, typically measured using the Pearl Index, and monitored the suppression of ovulation as an outcome. The study populations included women of reproductive age seeking a method of family planning.

Data collected from large-scale cohorts reported calculations of pregnancy rates across many thousands of exposure cycles. Research explored outcomes related to follicular growth and ovulation. Due to ethical constraints, contraceptive efficacy trials are not compared to a sugar pill (placebo).

Evidence for Use in Mild to Moderate Acne

Research for this use was explored in dedicated Phase III Randomized Controlled Trials (RCTs) and comparative clinical trials. These studies examined outcomes related to physical discomfort, such as changes in acne lesion counts (e.g., papules and pustules) and assessments using global clinical severity scores. The populations studied mainly included women diagnosed with mild to moderate papulopustular acne who also required contraception.

Controlled trials reported objective measurements documenting changes in acne lesion counts and described patterns in overall global severity scores in relation to placebo or other combined hormonal contraceptives. Findings describe group patterns; however, research is primarily focused on the mild to moderate end of the severity spectrum, and comprehensive comparative evidence is lacking.

Research on Related Hormonal and Cycle Symptoms

Mona HEXAL was evaluated in smaller, dedicated clinical trials and large post-marketing reports that examined endpoints relevant to its secondary indications. Studies monitored outcomes related to systemic or functional imbalance, such as changes in sebum excretion (oil production), mild hirsutism, and intensity/frequency of menstrual pain (dysmenorrhea). The evidence for these secondary outcomes is limited in scope, relying more heavily on observational data and smaller trials.

Follow-up Duration and Long-Term Research

The observation periods vary across the documented studies. Many efficacy trials monitored patients over intermediate periods of six months to one year. Data collection in some large, non-randomized cohorts extended the follow-up period up to two years. Research is ongoing to explore aspects of long-term outcomes that are not fully characterized by the initial, shorter-duration trials.

Frequently Asked Questions (FAQ)

Common questions about Mona HEXAL (FAQ)

Q: How quickly can I expect to see an effect from Mona HEXAL?

A: For its primary use in pregnancy prevention, official guidance defines the time period required before the contraceptive effect is established, which is essential information for healthcare providers when advising on the use of supplementary protection methods. When used to help manage acne, clinical studies indicate that observable changes in acne severity may be documented after several months of continuous use, consistent with the timeline of hormonal regulation.

Q: Are there any common over-the-counter medicines that interact with Mona HEXAL?

A: Regulatory information primarily warns about interactions with specific types of medicines that can significantly speed up the breakdown of hormones in the liver, such as certain antibiotics and seizure medications. Official documents do not generally identify common over-the-counter pain relievers, like paracetamol or ibuprofen, as substances that require a change in the use of this contraceptive.

Q: What happens if I miss a scheduled dose of Mona HEXAL?

A: The official product documentation provides specific, detailed protocols for managing a missed dose. The action required is dependent on the amount of time that has passed since the tablet was due and which week of the cycle the dose was missed in. Adherence to these official protocols is essential for maintaining the intended contraceptive effect.

Q: Does Mona HEXAL contain lactose or gluten, which could affect people with intolerances?

A: The official product documentation provides a complete list of all ingredients, including inactive components (excipients), to ensure patients with known allergies or intolerances, such as to lactose or gluten, can verify their eligibility before use.

Q: Can Mona HEXAL be taken with common pain relievers like paracetamol?

A: Official interaction warnings focus on medicines that may reduce the effectiveness of the contraceptive hormones by increasing their clearance from the body. Regulatory documents generally do not list common, non-inducing pain relievers like paracetamol (acetaminophen) as substances that require caution or additional protection.

Q: Are there any specific symptoms that should prompt immediate medical attention?

A: Official warnings describe specific symptoms that are associated with serious adverse reactions, such as blood clots (venous or arterial thromboembolism) or stroke. Regulatory guidance recommends immediate medical evaluation if symptoms like sudden severe chest or leg pain, or sudden vision or speech disturbances, are experienced.

Q: What is the typical duration of treatment with Mona HEXAL?

A: The regimen is established for ongoing, continuous use, typically repeated as long as the medication is desired and appropriate for the user. It is based on a 28-day cycle, which is maintained as long as the patient remains free from contraindications.

Q: Does Mona HEXAL interact with alcohol consumption?

A: Official regulatory documents typically do not list alcohol as a specific substance that alters the effectiveness of this type of combined hormonal contraceptive. However, official documents do not typically address alcohol beyond general health considerations.

Q: Does Mona HEXAL prevent a health issue or just treat the symptoms?

A: The medicine’s primary function is to prevent pregnancy by suppressing ovulation and modifying the reproductive environment. Its secondary application in managing acne is described as a treatment for symptoms related to the overactivity of male-type hormones (androgens).

Q: Is Mona HEXAL considered a 'first-line' treatment option?

A: Official regulatory documents define the medicine's role as a method of contraception or as a therapeutic option for patients with mild to moderate acne who also desire oral contraception. This description helps position it within the spectrum of treatment options for these specific conditions.

Q: What is the difference between Mona HEXAL and other similar sounding medicines?

A: Mona HEXAL is defined by its specific pairing of Chlormadinone Acetate and Ethinyl Estradiol. The official description highlights the documented antiandrogenic properties of the Chlormadinone Acetate component, which may differentiate it pharmacologically from other combined hormonal contraceptives.

Q: Does Mona HEXAL cause changes to weight or appetite?

A: Weight gain is listed as a common side effect in the official safety profile, meaning it affects a notable percentage of users. While weight changes are documented, changes in appetite are not explicitly listed in the most frequent categories of reported adverse reactions.

Q: Is it common for people to experience a headache when starting Mona HEXAL?

A: Headache is listed as a 'Very Common' side effect in the official safety profile, which means it may affect more than 1 in 10 users. While regulatory documents do not specify if this is limited to the start of treatment, it is one of the most frequently reported effects.

Q: Are there any food or drink restrictions while using Mona HEXAL?

A: The official administration instructions state that the tablets may be taken either with or without food. This indicates that there are no general food restrictions required to ensure the medication remains effective or safe.

Q: Are there any long-term health risks described for Mona HEXAL use?

A: Official warnings document serious health risks associated with the prolonged use of all combined hormonal contraceptives. These risks include an increased likelihood of blood clotting events (venous and arterial thromboembolism) and certain hormone-sensitive tumours.

Q: Can men use Mona HEXAL for any health condition?

A: The authorized uses for this medicine are established specifically for women of reproductive age. Regulatory documentation does not include information regarding its use in men.

Q: Does Mona HEXAL have any known effect on mood or anxiety levels?

A: Depressed mood and general mood changes are listed as Common side effects in the official safety profile. While these mood-related effects are reported, anxiety is not explicitly listed among the most common adverse reactions.

Q: Is it necessary to have regular medical tests while taking Mona HEXAL?

A: The official product information advises that continued medical supervision is required while using the medicine. This includes the need for regular medical examinations and checks, such as monitoring blood pressure.

Q: Does Mona HEXAL increase the risk of developing a specific type of infection?

A: The regulatory safety documents categorize reported side effects, which includes the 'Infections and Infestations' group. These categories may describe the specific types of infections, such as candidiasis (yeast infections), that have been reported by users.

Q: What should I do if the medicine does not seem to be working after a few weeks?

A: Regulatory guidance addresses situations of unachieved outcomes by recommending a re-evaluation of the patient's adherence to the regimen and an assessment for potential interactions with other medicines.

Q: Is there a link between Mona HEXAL and changes to blood pressure?

A: Official warnings indicate that combined hormonal contraceptives can, in some cases, be associated with the development of hypertension (high blood pressure). For this reason, regulatory documents recommend that a patient's blood pressure be monitored regularly during use.

Q: Does Mona HEXAL cause any changes to skin condition, like acne or rash?

A: Although the medicine is indicated for the treatment of mild to moderate acne, official safety data also lists other skin-related effects under less common adverse reactions. These include rash, hypersensitivity reactions, and certain benign and malignant tumours of the skin.

Q: Are there any age-related restrictions for using Mona HEXAL, particularly for older adults?

A: The authorized use is specified for women of reproductive age. Use is generally discontinued around the time of the transition to menopause, as the contraceptive function is no longer required and risks associated with hormonal use may change with age.

Q: Does using Mona HEXAL affect fertility or reproductive health?

A: The medicine is designed to temporarily affect fertility by preventing ovulation while it is being used. Official information states that a woman's ability to become pregnant typically returns to pre-treatment levels shortly after the medication is discontinued.

Q: Do studies show that Mona HEXAL is less effective over time (tolerance buildup)?

A: Official information does not indicate tolerance or a decrease in contraceptive effectiveness over time, provided the established hormonal regimen is consistently followed.

Q: Is it possible to be allergic to the inactive ingredients in Mona HEXAL?

A: Yes, official product information states that the medicine is strictly contraindicated (must not be used) if a patient has a known hypersensitivity or allergy not only to the active substances but also to any of the listed inactive excipients.

Q: Is there official information on Mona HEXAL's use in combination with other treatments for the same condition?

A: While the medicine is sometimes used as part of a therapeutic regimen, especially when treating acne, specific combination protocols with other therapies are not typically detailed in the official product information which focuses on the drug's safety and efficacy as a standalone product.

Q: Are there any specific visual or eye-related side effects mentioned in the drug safety data?

A: Yes, the official safety profile includes a category for 'Eye disorders' which describes specific adverse reactions that have been reported by users. These include visual disturbances and complications such as contact lens intolerance.

Q: Can Mona HEXAL be taken at any time of day, or is a specific time better?

A: Administration guidelines specify that the tablet must be taken at the same approximate time each day to ensure a consistent dosing interval is maintained. However, the documentation does not mandate a specific time of day, such as morning or evening, over another.

Q: Does Mona HEXAL impact the results of common blood tests?

A: Official product information warns that the use of combined hormonal contraceptives can interfere with the results of certain laboratory tests. This includes parameters relating to liver, kidney, thyroid, and adrenal function, as well as blood clotting factors.

Q: Can Mona HEXAL be used in patients with a history of depression?

A: Regulatory information advises that patients with a history of depression should be monitored, and discontinuation of the medicine may be considered if severe depression recurs during use, although a history of depression is not listed as an absolute contraindication.

How should Mona HEXAL be stored and disposed of?

Mona HEXAL (Chlormadinone Acetate/Ethinyl Estradiol) is a medicinal product that does not require any special storage conditions, such as refrigeration or protection from light, according to official regulatory labeling.

Storage Requirements

Condition Official Regulatory Rule
Temperature No special storage conditions required.
Child Safety Mandatory to keep out of the sight and reach of children.
Shelf-Life Must not be used after the expiry date (EXP) stated on the carton and blister.

Disposal Instructions

Official disposal protocols are mandatory to protect the environment:

  • Unused or expired medicines must not be thrown away via wastewater or with household waste.
  • Patients must ask a pharmacist for guidance on how to properly discard any no-longer-needed product. These specific measures help ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mona HEXAL found in:

A-Z Index: